| Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study |
|
American Journal of Hematology |
Aplastic Anemia |
| Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution |
|
Blood |
Aplastic Anemia |
| Eltrombopag in children with severe aplastic anemia |
|
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
| Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial |
|
Blood |
Aplastic Anemia |
| Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia |
|
Transplantation and Cellular Therapy |
Aplastic Anemia, Graft Versus Host Disease (GVHD) |
| Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
